Clinical trial
Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset…
NCT00268944 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00268944 |
|---|---|
| Title | Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support |
| Official title | Prospective, Open-label, Single-arm, Exploratory Study of the Effect and Safety of rhGAA in Patients With Advanced Late-onset Pompe Disease Who Are Receiving Respiratory Support |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pompe Disease (Late-onset), Glycogen Storage Disease Type II (GSD-II), Acid Maltase Deficiency Disease, Glycogenosis 2 |
| Intervention type | Biological |
| Interventions | Myozyme |
| Enrollment | 5 |
| Start date | Dec 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Dec 23, 2005 |
| Last update posted | Feb 5, 2014 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: